Key Takeaways
- Shares of Xenon Pharmaceuticals climbed 40% following positive Phase 3 X-TOLE2 trial results for azetukalner, which achieved its primary endpoint across both dosing cohorts.
- The higher 25 mg dosage demonstrated a 53.2% median reduction in monthly focal onset seizure frequency compared to baseline, while placebo showed only 10.4% reduction.
- These findings surpassed the earlier Phase 2b X-TOLE trial, which recorded a 34.6% placebo-adjusted median percentage reduction.
- More than half of participants receiving the 25 mg dose (54.8%) experienced at least a 50% decrease in seizure occurrence.
- The company intends to submit a New Drug Application (NDA) to the FDA during the third quarter of 2026.
Shares of Xenon Pharmaceuticals (XENE) exploded higher by 40% during Monday’s trading session following the biotech company’s announcement that azetukalner successfully achieved its primary endpoint in the Phase 3 X-TOLE2 clinical trial for focal onset seizures. The better-than-anticipated data triggered immediate buying at market open.
Xenon Pharmaceuticals Inc., XENE
The clinical study recruited 380 adult patients suffering from highly refractory epilepsy. These individuals had previously attempted a median of five different antiseizure therapies and continued to endure approximately 12.75 seizures monthly at the study’s commencement.
Patients administered the 25 mg dose of azetukalner demonstrated a median percentage reduction of -53.2% in monthly focal onset seizure frequency relative to baseline measurements. Those receiving placebo experienced merely -10.4% reduction. This translates to a placebo-adjusted differential of -42.7%.
This figure carries significant weight. The preceding Phase 2b X-TOLE trial had demonstrated a placebo-adjusted median percentage change of -34.6% among the 25 mg cohort. X-TOLE2 substantially exceeded this benchmark.
The lower 15 mg dose also delivered solid results, achieving a -34.5% median percentage change versus placebo, although the 25 mg outcomes generated the greatest market enthusiasm.
Secondary Measures Also Achieved
The study successfully met its primary secondary endpoint as well. Among the 25 mg cohort, 54.8% of subjects achieved a minimum 50% reduction in monthly seizure frequency โ referred to as the Responder Rate 50. This contrasted sharply with only 20.8% in the placebo arm. The 15 mg cohort registered 37.6%.
Out of 332 subjects completing the double-blind phase, 322 transitioned into the open-label extension portion of the study.
The safety data remained consistent with expectations. The most frequently reported adverse events included dizziness, headache, somnolence, and fatigue. Treatment withdrawal due to adverse events occurred in 14.5% of the 25 mg cohort, 4.8% of the 15 mg group, and 3.2% of placebo recipients.
According to the company’s announcement, Xenon CEO Ian Mortimer characterized the findings as demonstrating “the highest placebo-adjusted efficacy ever observed in a pivotal epilepsy study.”
Future Plans and Regulatory Timeline
Xenon intends to file an NDA with the FDA for azetukalner in focal onset seizures during Q3 2026. Regulatory approval would establish it as the first KV7 potassium channel opener commercially available for epilepsy treatment.
Analysts at Stifel suggested the robust results may prompt investors to increase their peak sales forecasts and penetration rate projections for the therapy.
Azetukalner offers several practical benefits compared to current treatment alternatives โ including once-daily administration, elimination of titration requirements, and absence of significant drug-drug interactions.
The complete X-TOLE2 dataset will be featured during an oral presentation at the American Academy of Neurology (AAN) Annual Meeting scheduled for April.
Xenon is simultaneously advancing azetukalner’s development for depression treatment, although that indication was not addressed in Monday’s data release.
The stock traded approximately 40% higher as of Monday morning, with the rally entirely attributed to the Phase 3 clinical data announcement.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
